CUBT / Curative Biotechnology, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

Tenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.40 Tenth Amendment to Transaction Documents This Tenth Amendment to the Transaction (this “Amendment”) is effective as of March 16, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd

Amended Employment Agreement with Paul Michaels dated September 14, 2023

Exhibit 10.35 AMENDMENT TO EMPLOYMENT AGREEMENT Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Paul M Michaels an individual (“the employee”) with an address of 3620 Gardens Parkway, Palm Beach Gardens, FL 443

Amendment Number 2 to Patent License Agreement -Exclusive Evaluation Option License dated November 17, 2023 between National Institute of Health and Curative Biotechnology, Inc. (f/k/a Connectyx Technologies Holdings Group)

Exhibit 10.32

Fifteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.45 Fifteenth Amendment to Transaction Documents This Fifteenth Amendment to the Transaction (this “Amendment”) is effective as of December 18, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Cor

As filed with the U.S. Securities and Exchange Commission on August 1, 2025

As filed with the U.S. Securities and Exchange Commission on August 1, 2025 Registration No. 333-279159 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1/A AMENDMENT NO. 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Curative Biotechnology, Inc. (Exact name of registrant as specified in its charter) Florida 2836 26-1412177 (State or other jurisdiction of i

Eleventh Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.41 Eleventh Amendment to Transaction Documents This Eleventh Amendment to the Transaction (this “Amendment”) is effective as of April 5, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate

Amended Employment Agreement with Barry Ginsberg dated September 14, 2023

Exhibit 10.37 AMENDMENT TO EMPLOYMENT AGREEMENT & RESIGNATION FROM BOARD OF DIRECTORS Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Dr. Barry Ginsberg an individual (“the employee”) with an address of 3601 NW

Amended Employment Agreement with Richard Garr dated September 14, 2023

Exhibit 10.34 AMENDMENT TO EMPLOYMENT AGREEMENT Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and I Richard Garr an individual (“the employee”) with an address of 1024 Casuarina Rd. Delray Beach FL 44384, now 880

Seventeenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.47

Articles of Amendment to the Articles of Incorporation, dated November 9, 2023

Exhibit 3.3

Ninth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.39 Ninth Amendment to Transaction Documents This Ninth Amendment to the Transaction (this “Amendment”) is effective as of February 17, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate B

Twenty First Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.53

Thirteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.43 Thirteenth Amendment to Transaction Documents This Thirteenth Amendment to the Transaction (this “Amendment”) is effective as of July 2, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corpor

Nineteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.51

Sixteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.46 Sixteenth Amendment to Transaction Documents This Sixteenth Amendment to the Transaction (this “Amendment”) is effective as of January 29, 2024 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corp

Twentieth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.52

Twelfth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.42 Twelfth Amendment to Transaction Documents This Twelfth Amendment to the Transaction (this “Amendment”) is effective as of May 2, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blv

Amended Employment Agreement with Paul Michaels dated February 28, 2024

Exhibit 10.36 2nd AMENDMENT TO EMPLOYMENT AGREEMENT Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Paul M Michaels an individual (“the employee”) with an address of 3620 Gardens Parkway, Palm Beach Gardens, FL

Amendment Number 1 to Patent License Agreement -Exclusive Evaluation Option License dated February 23, 2023 between National Institute of Health and Curative Biotechnology, Inc. (f/k/a Connectyx Technologies Holdings Group)

Exhibit 10.31

Eighth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.38 Eighth Amendment to Transaction Documents This Eighth Amendment to the Transaction (this “Amendment”) is effective as of January 31, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate

Eighteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.50

Consent of Salberg & Company

Exhibit 23.01 Consent of Independent Registered Public Accounting Firm We hereby consent to the use of our report dated July 31, 2025, on the financial statements of Curative Biotechnology, Inc. as of December 31, 2024 and 2023, and for each of the two years in the period ended December 31, 2024, included herein on the Amendment No.1 registration statement of Curative Biotechnology, Inc. on Form S

Amendment Number 1 to Patent License Agreement dated March 19, 2024 between National Institute of Health and Curative Biotechnology, Inc. (f/k/a Connectyx Technologies Holdings Group)

Exhibit 10.33 CONFIDENTIAL -NIH First Amendment of L-088-2021-0 Final -Curative March 6, 2024 Model 10-2015 Page 1 of 8 PUBLIC HEALTH SERVICE First Amendment This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control an

Fourteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.44 Fourteenth Amendment to Transaction Documents This Fourteenth Amendment to the Transaction (this “Amendment”) is effective as of December 1, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Co

Ninth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.39 Ninth Amendment to Transaction Documents This Ninth Amendment to the Transaction (this “Amendment”) is effective as of February 17, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate B

Amended Employment Agreement with Barry Ginsberg dated September 14, 2023

Exhibit 10.37 AMENDMENT TO EMPLOYMENT AGREEMENT & RESIGNATION FROM BOARD OF DIRECTORS Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Dr. Barry Ginsberg an individual (“the employee”) with an address of 3601 NW

Amendment Number 1 to Patent License Agreement -Exclusive Evaluation Option License dated February 23, 2023 between National Institute of Health and Curative Biotechnology, Inc. (f/k/a Connectyx Technologies Holdings Group)

Exhibit 10.31 CONFIDENTIAL -NIH First Amendment of L-009-2021-1 Final Curative Biotechnology February 15, 2023 Model 10-2015 Page 1 of 11 PUBLIC HEALTH SERVICE Amendment This Agreement is based on the model Amendment Agreement adopted by the US Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease

Sixteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.46 Sixteenth Amendment to Transaction Documents This Sixteenth Amendment to the Transaction (this “Amendment”) is effective as of January 29, 2024 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corp

Amended Employment Agreement with Richard Garr dated September 14, 2023

Exhibit 10.34 AMENDMENT TO EMPLOYMENT AGREEMENT Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and I Richard Garr an individual (“the employee”) with an address of 1024 Casuarina Rd. Delray Beach FL 44384, now 880

Thirteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.43 Thirteenth Amendment to Transaction Documents This Thirteenth Amendment to the Transaction (this “Amendment”) is effective as of July 2, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corpor

As filed with the U.S. Securities and Exchange Commission on May 6, 2024

As filed with the U.S. Securities and Exchange Commission on May 6, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Curative Biotechnology, Inc. (Exact name of registrant as specified in its charter) Florida 2836 26-1412177 (State or other jurisdiction of incorporation or organizatio

Eleventh Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.41 Eleventh Amendment to Transaction Documents This Eleventh Amendment to the Transaction (this “Amendment”) is effective as of April 5, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate

Registration Fee Table

Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) CURATIVE BIOTECHNOLOGY INC.

Amended Employment Agreement with Paul Michaels dated September 14, 2023

Exhibit 10.35 AMENDMENT TO EMPLOYMENT AGREEMENT Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Paul M Michaels an individual (“the employee”) with an address of 3620 Gardens Parkway, Palm Beach Gardens, FL 443

Eighth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.38 Eighth Amendment to Transaction Documents This Eighth Amendment to the Transaction (this “Amendment”) is effective as of January 31, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate

Amendment Number 2 to Patent License Agreement -Exclusive Evaluation Option License dated November 17, 2023 between National Institute of Health and Curative Biotechnology, Inc. (f/k/a Connectyx Technologies Holdings Group)

Exhibit 10.32 CONFIDENTIAL -NIH Second Amendment of L-009-2021-0 Final Curative Biotechnology November 17, 2023 Model 10-2015 Page 1 of 10 PUBLIC HEALTH SERVICE Amendment This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disea

Fourteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.44 Fourteenth Amendment to Transaction Documents This Fourteenth Amendment to the Transaction (this “Amendment”) is effective as of December 1, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Co

Tenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.40 Tenth Amendment to Transaction Documents This Tenth Amendment to the Transaction (this “Amendment”) is effective as of March 16, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd

Fifteenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.45 Fifteenth Amendment to Transaction Documents This Fifteenth Amendment to the Transaction (this “Amendment”) is effective as of December 18, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Cor

Articles of Amendment to the Articles of Incorporation, dated November 9, 2023

Exhibit 3.3

Seventeenth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.47

Amended Employment Agreement with Paul Michaels dated February 28, 2024

Exhibit 10.36 2nd AMENDMENT TO EMPLOYMENT AGREEMENT Amendment to Employment Agreement (“the agreement”) dated September 1, 2020 between Connectyx Technologies Holding Group, now Curative Biotechnology Inc. 1825 NW Corporate Blvd suite 110 Boca Raton FL 33431 (hereinafter “the Company” and Paul M Michaels an individual (“the employee”) with an address of 3620 Gardens Parkway, Palm Beach Gardens, FL

Twelfth Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.42 Twelfth Amendment to Transaction Documents This Twelfth Amendment to the Transaction (this “Amendment”) is effective as of May 2, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blv

Amendment Number 1 to Patent License Agreement dated March 19, 2024 between National Institute of Health and Curative Biotechnology, Inc. (f/k/a Connectyx Technologies Holdings Group)

Exhibit 10.33 CONFIDENTIAL -NIH First Amendment of L-088-2021-0 Final -Curative March 6, 2024 Model 10-2015 Page 1 of 8 PUBLIC HEALTH SERVICE First Amendment This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control an

Curative Biotechnology, Inc. 1825 NW Corporate Blvd, Suite 110 Boca Raton, FL 33431

Curative Biotechnology, Inc. 1825 NW Corporate Blvd, Suite 110 Boca Raton, FL 33431 January 31, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, N.E. Washington, D.C. 20549 Re: Curative Biotechnology, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-268194 Ladies and Gentlemen: Pursu

Seventh Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.29 Seventh Amendment to Transaction Documents This Seventh Amendment to the Transaction (this “Amendment”) is effective as of January 11, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporat

As filed with the Securities and Exchange Commission on January 24, 2023

As filed with the Securities and Exchange Commission on January 24, 2023 Registration No.

Seventh Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.29 Seventh Amendment to Transaction Documents This Seventh Amendment to the Transaction (this “Amendment”) is effective as of January 11, 2023 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporat

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 (except for Note 2, as to which the date is September 26, 2022) relating to the

As filed with the Securities and Exchange Commission on January 12, 2023

As filed with the Securities and Exchange Commission on January 12, 2023 Registration No.

Sixth Amendment to March 2022 Convertible Note Transaction Documents

EX-10.28 10 ex10-28.htm Exhibit 10.28 Sixth Amendment to Transaction Documents This Sixth Amendment to the Transaction (this “Amendment”) is effective as of December 16, 2022 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of busines

As filed with the Securities and Exchange Commission on January 9, 2023

As filed with the Securities and Exchange Commission on January 9, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Curative Biotechnology, Inc

8-A12B/A 1 form8a-12ba.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A/A (Amendment No. 1) FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Curative Biotechnology, Inc. (Exact name of registrant as specified in its charter) Florida 71-1550658 (State or other jurisdiction of incorporation o

As filed with the Securities and Exchange Commission on November 30, 2022

As filed with the Securities and Exchange Commission on November 30, 2022 Registration No.

Third Amendment to March 2022 Convertible Note Transaction Documents

EX-10.25 3 ex10-25.htm Exhibit 10.25 Third Amendment to Transaction Documents This Third Amendment to the Transaction (this “Amendment”) is effective as of October 14, 2022 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business

Fourth Amendment to March 2022 Convertible Note Transaction Documents

EX-10.26 4 ex10-26.htm Exhibit 10.26 Fourth Amendment to Transaction Documents This Second Amendment to the Transaction (this “Amendment”) is effective as of November 2, 2022 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of busines

Second Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.24 Second Amendment to Transaction Documents This Second Amendment to the Transaction (this ?Amendment?) is effective as of October 2, 2022 (?Effective Date?), by and between Puritan Partners LLC, a New York limited liability company (?Puritan Partners?) and Curative Biotechnology, Inc., a Florida corporation (the ?Company?), having its principal place of business at 1825 NW Corporate B

Fifth Amendment to March 2022 Convertible Note Transaction Documents

EX-10.27 5 ex10-27.htm Exhibit 10.27 Fifth Amendment to Transaction Documents This Fifth Amendment to the Transaction (this “Amendment”) is effective as of November 16, 2022 (“Effective Date”), by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 (except for Note 2, as to which the date is September 26, 2022) relating to the

As filed with the Securities and Exchange Commission on November 16, 2022

As filed with the Securities and Exchange Commission on November 16, 2022 Registration No.

Consent of Lucosky Brookman LLP (contained in Exhibit 5.01 hereto)

Exhibit 5.1 LUCOSKY BROOKMAN LLP November 16, 2022 101 Wood Avenue South 5th floor Woodbridge, NJ 08830 T - (732) 395-4400 F - (732) 395-4401 Curative Biotechnology, Inc. 1825 NW Corporate Blvd, Suite 110 Boca Raton, FL 33431 111 Broadway Suite 807 New York, NY 10006 T - (212) 332-8160 F - (212) 332-8161 www.lucbro.com Re: Amendment No. 1 to Registration Statement on Form S-1 Ladies and Gentlemen:

First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc.

Exhibit 10.15 FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENT THIS FIRST AMENDMENT (the ?Amendment?) to the License, Funding and Operational Agreement between Mid-Atlantic BioTherapeutics, Inc. (?Licensor?) and Curative Biotechnology, Inc. (?Licensee?) executed October 1, 2021 for a COVID-19 Vaccine (the ?Agreement?), is made by Licensor and Licensee, WITNESSETH: WHEREAS, the Licenso

Form of Lock Up Agreement for March 2022 Offering

Exhibit 10.21 LOCK-UP AGREEMENT March 2, 2022 Each Purchaser referenced below: Re: Securities Purchase Agreement, dated as of March 2, 2022 (the ?Purchase Agreement?), between Curative Biotechnology, Inc., a Florida corporation (the ?Company?), and the purchaser signatory thereto (the ?Purchaser?) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the ?Letter Agree

First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc.

Exhibit 10.14 FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENT THIS IS THE FIRST AMENDMENT (the ?Amendment?) to the License, Funding and Operational Agreement for rabies immunotherapy (the ?Agreement?) between Mid-Atlantic BioTherapeutics, Inc. (?Licensor?) and Curative Biotechnology, Inc., formerly Connectyx, (?Licensee?) originally executed September 30th, 2020. WITNESSETH: WHEREAS,

Securities Purchase Agreement for March 2022 Offering

Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the ?Company?) and the Purchaser identified on the signature pages hereto (including their successors and assigns

Exclusive Option Agreement for Purchase of Patent Rights dated September 30, 2020 between Curative Biotechnology (fka Connectyx Technologies Holdings Group) and IEM Inc.

Exhibit 10.10 EXCLUSIVE OPTION AGREEMENT FOR PURCHASE OF PATENT RIGHTS This Agreement is made as of the date set forth above the signatures of the parties below (the ?EFFECTIVE DATE?), by and between IEM INC., A Florida Corporation located in Palm Beach County (?IEM?) and CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC., A Florida Corporation located in Palm Beach County (?CONNECTYX?). RECITALS: A. WHE

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 (except for Note 2, as to which the date is September 26, 2022) relating to the

Fourth Amended and Restated Articles of Incorporation dated January 27, 2021

EX-3.01 3 ex3-01.htm Exhibit 3.01 FOURTH AMENDED AND RESTATED ARTICLES OF INCORPORATION OF CURATIVE BIOTECHNOLOGY, INC. January 27, 2021 Paul M Michaels, being the CEO and Director of Curative Biotechnology, Inc., a corporation duly organized under the Business Corporation Act of the State of Florida (the “Corporation”), hereby certifies that: 1. The name of the Corporation is Curative Biotechnolo

Specimen of Series B Preferred Stock

EX-4.03 8 ex4-03.htm Exhibit 4.03

Form of Common Stock Purchase Warrant issued to Paul Michaels on June 11, 2021

Exhibit 4.11 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Common Stock Purchase warrant issued to Consultant on December 3, 2020

Exhibit 4.09 WARRANT: B-[*] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E

Form of Common Stock Purchase Warrant issued to Certain Consultants in May 2021

Exhibit 4.05 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Specimen Series A Preferred Stock

Exhibit 4.02

Form of Underwriting Agreement

Exhibit 1.01 Underwriting Agreement [●], 2022 Aegis Capital Corp. 810 7th Avenue, 18th Floor New York, NY 10019 Ladies and Gentlemen: Curative Biotechnology, Inc., a Florida corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] units (each, a “Closing Unit”), wi

Employment Agreement with Paul Michaels dated October 1, 2020

Exhibit 10.08 EMPLOYMENT AGREEMENT Employment agreement (“the Agreement”) dated as of October 1, 2020 between Connectyx Technologies Holdings Group 1825 NW Corporate Boulevard, Suite 110 Boca Raton, FL 33431 (“the Company”) and Paul M. Michaels, an individual with an address of 7922 La Mirada Drive Boca Raton, FL 33433 (“the employee”) WHEREAS, the Company desires to retain the services of Employe

Employment Agreement with Richard Garr dated October 1, 2020

Exhibit 10.06 EMPLOYMENT AGREEMENT Employment agreement (?the Agreement?) dated as of October 1, 2020 between Connectyx Technologies Holdings Group 1825 NW Corporate Boulevard, Suite 110 Boca Raton, FL 33431 (?the Company?) and I Richard Garr, an individual with an address of 1024 Casuarina Road Delray Beach, FL 33483 (?the employee?) WHEREAS, the Company desires to retain the services of Employee

Form of Subscription Agreement for Investor Offerings on May 21, 2021

Exhibit 10.02 May 21, 2021 Curative Biotechnology, Inc. Attn: I. Richard Garr, President 1825 NW Corporate Blvd. Boca Raton, FL 33431 Email: [email protected] Re: Curative Biotechnology, Inc. - Subscription for Shares of Common Stock Ladies and Gentlemen: The undersigned hereby acknowledges and agrees to the following: 1. The undersigned hereby subscribes for 10,000,000 shares (the ?Shares?) of Common

Form of Subscription Agreement for Investor Offerings in August 2021

Exhibit 10.01 [DATE] Curative Biotechnology, Inc. Attn: I. Richard Garr, President 1825 NW Corporate Blvd. Boca Raton, FL 33431 Email: [*] Re: Curative Biotechnology, Inc. - Subscription for Shares of Common Stock Ladies and Gentlemen: The undersigned hereby acknowledges and agrees to the following: 1. The undersigned hereby subscribes for [*] Units, with each Unit consisting of: (i) [?] shares of

Cooperative Research and Development Agreement for Intramura-PhS Clinical Research

Exhibit 10.22 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH This Agreement is based on the model Cooperative Research and Development Agreement (?CRADA?) adopted by the U.S. Public Health Service (?PHS?) Technology Transfer Policy Board for use by components of the National Institutes of Health (?NIH?), the Centers for Disease Control and

Warrant for March 2022 Offering

Exhibit 10.20 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Specimen of Common Stock Certificate

Exhibit 4.01

Form of Common Stock Purchase Warrant issued to Marc Drimer on July 14, 2021

Exhibit 4.12 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Governance and Nominating Committee Charter

Exhibit 99.03 CURATIVE BIOTECHNOLOGY, INC. NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER (As adopted on August 6, 2022) Purpose The purpose of the Nominating and Corporate Governance Committee (the ?Committee?) of the Board of Directors (the ?Board?) of Curative Biotechnology, Inc. (the ?Company?) is to assist the Board in the discharge of its responsibilities relating to: (a) the identifi

Form of Restricted Stock Unit Agreement for 2021 Equity Incentive Plan

Exhibit 4.17 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Curative Biotechnology, Inc. 2021 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Restricted Stock Unit Agreement, which includes the Notice of Restricted Stock Unit Grant

Form of Warrant issued to investors on May 21, 2021

Exhibit 4.07 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Security Agreement for March 2022 Offering

Exhibit 10.18 SECURITY AGREEMENT SECURITY AGREEMENT, dated as of March 2, 2022 (this ?Agreement?), between Curative Biotechnology, Inc., a Florida limited liability company (the ?Company? or the ?Debtor? and collectively with any other Debtor from time to time hereunder, the ?Debtors?) and the holders of the Company?s 12.5% Senior Secured Note due March 2, 2023 in aggregate principal amount of $1,

Employment Agreement with Barry Ginsberg dated October 1, 2020

Exhibit 10.07 EMPLOYMENT AGREEMENT Employment agreement (?the Agreement?) dated as of October 1, 2020 between Connectyx Technologies Holdings Group 1825 NW Corporate Boulevard, Suite 110 Boca Raton, FL 33431 (?the Company?) and Dr. Barry A. Ginsberg, an individual with an address of 3601 NW 24th Avenue, Boca Raton, FL 33431 (?the employee?) WHEREAS, the Company desires to retain the services of Em

Form of Note Issued to Investors between November 2020 and January 2021

Exhibit 10.03 FIXED PAYMENT BRIDGE NOTE LENDER: [*] BORROWER: Connectyx Group Holdings Company, Inc. A Florida corporation whose address is 1825 NW Corporate Blvd. Boca Raton Florida, 33431 CLOSING DATE: [*] BORROWERS PROMISE TO PAY: $[*]([*] DOLLARS), an amount referred to as the” payment amount” in return for the loan that Borrower has received for $[*] ([*] DOLLARS) to the Lender on or before t

Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

Exhibit 10.11 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT ? EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (?PHS?) Technology Transfer Policy Board for use by components of the National Institutes of Health (?NIH?), the Centers for Disease Control and Prevention (?CDC?), and the Food and Drug Administration (?FDA?), wh

License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

Exhibit 10.13 LICENSE, FUNDING AND OPERATIONAL AGREEMENT This License Agreement (this ?Agreement?) is made and is effective this 30th day of September, 2020, (the ?Effective Date?) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (?Licensor?) and Connectyx (hereinafter CTYX) Technologies Holdings Group, Inc., a Florida corporation (?Licensee?), and David Horn, L

Secured Convertible Promissory Note for March 2022 Offering

Exhibit 10.17 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI

Form of Warrant Agency Agreement

Exhibit 10.24 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this ?Warrant Agreement?) dated as of [?], 2022 (the ?Issuance Date?) is between Curative Biotechnology, Inc., a Florida corporation (the ?Company?), and Issuer Direct Corporation (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dated [?], 2022, by and among t

Articles of Amendment to the Articles of Incorporation, dated September 26, 2022

Exhibit 3.02

Form of Stock Option Grant for 2021 Equity Incentive Plan

Exhibit 4.15 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Curative Biotechnology, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the “Notice of Grant”), the Terms and Conditions of Stock Option

Form of Consultant Warrants issued between December 2020 and January 2021

Exhibit 4.10 WARRANT: B-[*] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E

Amended and Restated Bylaws of Curative Biotechnology, Inc. dated March 29, 2021

Exhibit 3.03 AMENDED AND RESTATED BYLAWS OF CURATIVE BIOTECHNOLOGY, INC. (amended and restated on March 29, 2021) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Curative Biotechnology, Inc. shall be as designated in its certificate of incorporation, as may be amended and restated (?Certificate?) and as may be amended or changed by the corporation?s board of directors f

Specimen of Series C Preferred Stock

Exhibit 4.04

Form of Warrant issued to Investors in Note Offering from November 2020 through January 2021

Exhibit 4.08 WARRANT: A-[*] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E

Form of Common Stock Purchase Option issued to Catherine Sohn pursuant to Consulting Agreement dated September 27, 2021

Exhibit 4.13 CURATIVE BIOTECHNOLOGY, INC. NOTICE OF GRANT You have been granted a Nonstatutory Stock Option to purchase Common Stock of the Company, subject to the terms and conditions of this agreement, as follows: Name of Optionee: Sohn Health Strategies LLC Date of Grant: September 27, 2021 Vesting Commencement Date: September 27, 2021 Exercise Price per Share: $0.11 Total Number of Shares Gran

Form of Restricted Stock Award Agreement for 2021 Equity Incentive Plan

Exhibit 4.16 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Curative Biotechnology, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Award Agreement (the “Award Agreement”). I. NOTICE OF RESTRICTED STOCK GRANT Participant Name: Address: You ha

Compensation Committee Charter

Exhibit 99.02 CURATIVE BIOTECHNOLOGY, INC. COMPENSATION COMMITTEE CHARTER (As adopted on August 6, 2022) Purpose The purpose of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Curative Biotechnology, Inc. (the “Company”) is to assist the Board in the discharge of its responsibilities relating to: (a) the compensation of the Company’s directors and officers;

2021 Equity Incentive Plan

Exhibit 4.14 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan . The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors and Consultants, and ● to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock

Form of Common Stock Purchase Warrant issued to Investors in August 2021

Exhibit 4.06 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Code of Ethics and Business Conduct

Exhibit 14.01 Curative Biotechnology, Inc. Code of Ethics and Business Conduct 1. Introduction. 1.1 The Board of Directors (?Board?) of Curative Biotechnology, Inc. (together with its subsidiaries, the ?Company?) has adopted this Code of Ethics and Business Conduct (the ?Code?) in order to: (a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of in

Intellectual Property Security Agreement for March 2022 Offering

Exhibit 10.19 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (?IP Security Agreement?) dated as of March 2, 2022, is made and entered into by and among Curative Biotechnology, Inc., a Florida corporation (the ?Company?), any subsidiary of the Company that is a signatory hereto either now joined or joined in the future (such subsidiaries, together with the Co

Consulting Agreement dated September 27, 2021

Exhibit 10.05 Sohn Health Strategies SPECIAL ADVISOR TO THE BOARD OF DIRECTORS AND THE CEO AGREEMENT THIS AGREEMENT is made and entered into effective as of SEPTEMBER 27, 2021, (the ?Effective Date?), by and between Curative Biotechnology Inc., a Florida corporation (the ?Company?) with its principal place of business located at 1825 NW Corporate Blvd #110 Boca Raton, Florida , and Sohn Health Str

Form of warrant to be issued in Underwritten Offering

Exhibit 4.19 COMMON STOCK PURCHASE WARRANT Curative biotechnology, inc. Warrant Shares: Initial Exercise Date: Issue Date: CUSIP: THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder,? provided that a ?Holder? shall include, if the Warrants are held in ?street name,? a Participant, any designee appointed by such Participant and each ?be

Form of Underwriter Warrant

Exhibit 4.18 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [?], 2022 (THE ?EFFECTIV

As filed with the Securities and Exchange Commission on November 7, 2022

As filed with the Securities and Exchange Commission on November 7, 2022 Registration No.

First Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.23 First Amendment to Transaction Documents This First Amendment to the Transaction (this ?Amendment?) is entered into as of August 18, 2022, by and between Puritan Partners LLC, a New York limited liability company (?Puritan Partners?) and Curative Biotechnology, Inc., a Florida corporation (the ?Company?), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Bo

Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

Exhibit 10.12 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT ? EXCLUSIVE EVALUATION OPTION LICENSE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (?PHS?) Technology Transfer Policy Board for use by components of the National Institutes of Health (?NIH?), the Centers for Disease Control and Prevention (?CDC?), and the Food and Drug

License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc.

Exhibit 10.09 LICENSE, FUNDING AND OPERATIONAL AGREEMENT This License Agreement (this ?Agreement?) is made and is effective this 1st day of October 2021, (the ?Effective Date?) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (?Licensor?) and Curative Biotechnology, Inc. (hereinafter CUBT), a Delaware corporation (?Licensee?), and David Horn, LLC as Licensor to

Settlement Agreement dated August 9, 2021

Exhibit 10.04 SETTLEMENT AGREEMENT AND RELEASE THIS SETTLEMENT AGREEMENT AND RELEASE (the ?Settlement Agreement?), is made and entered into as of this 9th day of August 2021 by and between: (i) FORTIFIED MANAGEMENT GROUP, LLC (?Fortified?) and JODY R. SAMUELS (?Samuels?) on the one hand; and CURATIVE BIOTECHNOLOGY, INC. f/k/a CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC., on the other hand (?Curativ

Registration Fee Table

EX-FILING FEES 54 ex107.htm Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) CURATIVE BIOTECHNOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2

Audit Committee Charter

Exhibit 99.01 CURATIVE BIOTECHNOLOGY, INC. AUDIT COMMITTEE CHARTER (As adopted on August 6, 2022) Purpose The purpose of the Audit Committee (the ?Committee?) of the Board of Directors (the ?Board?) of Curative Biotechnology, Inc. (the ?Company?) is to assist the Board in the discharge of its oversight responsibilities regarding: (1) the quality and integrity of the Company?s financial statements;

Curative Biotechnology, Inc. 1825 NW Corporate Blvd, Suite 110 Boca Raton, FL 33431

Curative Biotechnology, Inc. 1825 NW Corporate Blvd, Suite 110 Boca Raton, FL 33431 October 31, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Energy & Transportation 100 F Street, N.E. Washington, D.C. 20549 Re: Curative Biotechnology, Inc. Request for Withdrawal of Registration Statement on Form S-1 File No. 333-264339 Ladies and Gentlemen: Pursu

October 11, 2022

October 11, 2022 Jason Drory Division of Corporation Finance United States Securities and Exchange Commission Washington, DC 20549 RE: Curative Biotechnology, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Curative Biotechnology, Inc. (Exact name of reg

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Curative Biotechnology, Inc. (Exact name of registrant as specified in its charter) Florida 71-1550658 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification

As filed with the Securities and Exchange Commission on September 30, 2022

As filed with the Securities and Exchange Commission on September 30, 2022 Registration No.

September 30, 2022

September 30, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Margaret Schwartz Re: Curative Biotechnology, Inc. Amendment No. 8 to Registration Statement on Form S-1 Filed September 28, 2022 File No. 333-264339 Ladies and Gentlemen: On behal

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

Registration Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc.

Form of Common Stock Purchase Option issued to Catherine Sohn pursuant to Consulting Agreement dated September 27, 2021

EX-4.13 2 ex4-13.htm Exhibit 4.13 CURATIVE BIOTECHNOLOGY, INC. NOTICE OF GRANT You have been granted a Nonstatutory Stock Option to purchase Common Stock of the Company, subject to the terms and conditions of this agreement, as follows: Name of Optionee: Sohn Health Strategies LLC Date of Grant: September 27, 2021 Vesting Commencement Date: September 27, 2021 Exercise Price per Share: $0.11 Total

Consent of Silvestre Law Group (contained in Exhibit 5.01 hereto)

Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 2629 Townsgate Road #215 Westlake Village, CA 91361 (818) 597-7552 Fax (805) 553-9367 September 29, 2022 Curative Biotechnology, Inc. 1825 NW Corporate Blvd. Suite 110 Boca Raton, FL 33431 Re: Registration Statement on Form S-1 (File No. 333-264339) Ladies and Gentlemen: We have acted as counsel to Curative Biotechnology, Inc., a Florida corporation (the ?Com

Form of Underwriter Agreement

Exhibit 1.01 Underwriting Agreement [●], 2022 Aegis Capital Corp. 810 7th Avenue, 18th Floor New York, NY 10019 Ladies and Gentlemen: Curative Biotechnology, Inc., a Florida corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] shares of common stock (the “Firm

Consent of Silvestre Law Group (contained in Exhibit 5.01 hereto)

Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 2629 Townsgate Road #215 Westlake Village, CA 91361 (818) 597-7552 Fax (805) 553-9367 September 28, 2022 Curative Biotechnology, Inc. 1825 NW Corporate Blvd. Suite 110 Boca Raton, FL 33431 Re: Registration Statement on Form S-1 (File No. 333-264339) Ladies and Gentlemen: We have acted as counsel to Curative Biotechnology, Inc., a Florida corporation (the “Com

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

Registration Fee Table

EX-FILING FEES 5 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price (1) Fee Rate Amount

As filed with the Securities and Exchange Commission on September 28, 2022

As filed with the Securities and Exchange Commission on September 28, 2022 Registration No.

Security Agreement for March 2022 Offering

Exhibit 10.18 SECURITY AGREEMENT SECURITY AGREEMENT, dated as of March 2, 2022 (this ?Agreement?), between Curative Biotechnology, Inc., a Florida limited liability company (the ?Company? or the ?Debtor? and collectively with any other Debtor from time to time hereunder, the ?Debtors?) and the holders of the Company?s 12.5% Senior Secured Note due March 2, 2023 in aggregate principal amount of $1,

First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc.

EX-10.14 9 ex10-14.htm Exhibit 10.14 FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENT THIS IS THE FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement for rabies immunotherapy (the “Agreement”) between Mid-Atlantic BioTherapeutics, Inc. (“Licensor”) and Curative Biotechnology, Inc., formerly Connectyx, (“Licensee”) originally executed September 30th, 202

Consulting Agreement dated September 27, 2021

Exhibit 10.05 Sohn Health Strategies SPECIAL ADVISOR TO THE BOARD OF DIRECTORS AND THE CEO AGREEMENT THIS AGREEMENT is made and entered into effective as of SEPTEMBER 27, 2021, (the ?Effective Date?), by and between Curative Biotechnology Inc., a Florida corporation (the ?Company?) with its principal place of business located at 1825 NW Corporate Blvd #110 Boca Raton, Florida , and Sohn Health Str

Amended and Restated Bylaws of Curative Biotechnology, Inc. dated March 29, 2021

EX-3.02 2 ex3-02ii.htm Exhibit 3.02(ii) AMENDED AND RESTATED BYLAWS OF CURATIVE BIOTECHNOLOGY, INC. (amended and restated on March 29, 2021) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Curative Biotechnology, Inc. shall be as designated in its certificate of incorporation, as may be amended and restated (“Certificate”) and as may be amended or changed by the corpora

September 9, 2022

CORRESP 1 filename1.htm September 9, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Margaret Schwartz Re: Curative Biotechnology, Inc. Registration Statement on Form S-1 Filed September 1, 2022 File No. 333-264339 Ladies and Gentlemen: On be

Warrant for March 2022 Offering

EX-10.20 15 ex10-20.htm Exhibit 10.20 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUA

Settlement Agreement dated August 9, 2021

Exhibit 10.04 SETTLEMENT AGREEMENT AND RELEASE THIS SETTLEMENT AGREEMENT AND RELEASE (the “Settlement Agreement”), is made and entered into as of this 9th day of August 2021 by and between: (i) FORTIFIED MANAGEMENT GROUP, LLC (“Fortified”) and JODY R. SAMUELS (“Samuels”) on the one hand; and CURATIVE BIOTECHNOLOGY, INC. f/k/a CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC., on the other hand (“Curativ

License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc.

EX-10.09 6 ex10-09.htm Exhibit 10.09 LICENSE, FUNDING AND OPERATIONAL AGREEMENT This License Agreement (this “Agreement”) is made and is effective this 1st day of October 2021, (the “Effective Date”) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (“Licensor”) and Curative Biotechnology, Inc. (hereinafter CUBT), a Delaware corporation (“Licensee”), and David Ho

License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

EX-10.13 8 ex10-13.htm Exhibit 10.13 LICENSE, FUNDING AND OPERATIONAL AGREEMENT This License Agreement (this “Agreement”) is made and is effective this 30th day of September, 2020, (the “Effective Date”) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (“Licensor”) and Connectyx (hereinafter CTYX) Technologies Holdings Group, Inc., a Florida corporation (“Licens

First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc.

EX-10.15 10 ex10-15.htm Exhibit 10.15 FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENT THIS FIRST AMENDMENT (the “Amendment”) to the License, Funding and Operational Agreement between Mid-Atlantic BioTherapeutics, Inc. (“Licensor”) and Curative Biotechnology, Inc. (“Licensee”) executed October 1, 2021 for a COVID-19 Vaccine (the “Agreement”), is made by Licensor and Licensee, WITNESSE

Amendment to March 2022 Convertible Note Transaction Documents

Exhibit 10.23 First Amendment to Transaction Documents This First Amendment to the Transaction (this “Amendment”) is entered into as of August 18, 2022, by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corporate Blvd., Suite 110 Bo

Intellectual Property Security Agreement for March 2022 Offering

EX-10.19 14 ex10-19.htm Exhibit 10.19 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (“IP Security Agreement”) dated as of March 2, 2022, is made and entered into by and among Curative Biotechnology, Inc., a Florida corporation (the “Company”), any subsidiary of the Company that is a signatory hereto either now joined or joined in the future (such subsidiari

Consent of Silvestre Law Group (contained in Exhibit 5.01 hereto)

Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 2629 Townsgate Road #215 Westlake Village, CA 91361 (818) 597-7552 Fax (805) 553-9367 September 9, 2022 Curative Biotechnology, Inc. 1825 NW Corporate Blvd. Suite 110 Boca Raton, FL 33431 Re: Registration Statement on Form S-1 (File No. 333-264339) Ladies and Gentlemen: We have acted as counsel to Curative Biotechnology, Inc., a Florida corporation (the ?Comp

As filed with the Securities and Exchange Commission on September 9, 2022

As filed with the Securities and Exchange Commission on September 9, 2022 Registration No.

Registration Fee Table

EX-FILING FEES 19 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount

Secured Convertible Promissory Note for March 2022 Offering

EX-10.17 12 ex10-17.htm Exhibit 10.17 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU

Securities Purchase Agreement for March 2022 Offering

EX-10.16 11 ex10-16.htm Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the “Company”) and the Purchaser identified on the signature pages hereto (including thei

Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

Exhibit 10.12 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT ? EXCLUSIVE EVALUATION OPTION LICENSE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (?PHS?) Technology Transfer Policy Board for use by components of the National Institutes of Health (?NIH?), the Centers for Disease Control and Prevention (?CDC?), and the Food and Drug

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

Form of Lock Up Agreement for March 2022 Offering

EX-10.21 16 ex10-21.htm Exhibit 10.21 LOCK-UP AGREEMENT March 2, 2022 Each Purchaser referenced below: Re: Securities Purchase Agreement, dated as of March 2, 2022 (the “Purchase Agreement”), between Curative Biotechnology, Inc., a Florida corporation (the “Company”), and the purchaser signatory thereto (the “Purchaser”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agre

Amendment to March 2022 Convertible Note Transaction Documents

EX-10.23 3 ex10-23.htm Exhibit 10.23 First Amendment to Transaction Documents This First Amendment to the Transaction (this “Amendment”) is entered into as of August 18, 2022, by and between Puritan Partners LLC, a New York limited liability company (“Puritan Partners”) and Curative Biotechnology, Inc., a Florida corporation (the “Company”), having its principal place of business at 1825 NW Corpor

Registration Fee Table

EX-FILING FEES 5 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount o

As filed with the Securities and Exchange Commission on September 1, 2022

As filed with the Securities and Exchange Commission on September 1, 2022 Registration No.

Consent of Silvestre Law Group (contained in Exhibit 5.01 hereto)

Exhibit 5.01 SILVESTRE LAW GROUP, P.C. 2629 Townsgate Road #215 Westlake Village, CA 91361 (818) 597-7552 Fax (805) 553-9367 September 1, 2022 Curative Biotechnology, Inc. 1825 NW Corporate Blvd. Suite 110 Boca Raton, FL 33431 Re: Registration Statement on Form S-1 (File No. 333-264339) Ladies and Gentlemen: We have acted as counsel to Curative Biotechnology, Inc., a Florida corporation (the “Comp

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

Audit Committee Charter

EX-99.01 3 ex99-01.htm Exhibit 99.01 CURATIVE BIOTECHNOLOGY, INC. AUDIT COMMITTEE CHARTER (As adopted on August 6, 2022) Purpose The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Curative Biotechnology, Inc. (the “Company”) is to assist the Board in the discharge of its oversight responsibilities regarding: (1) the quality and integrity of the Company’

Governance and Nominating Committee Charter

Exhibit 99.03 CURATIVE BIOTECHNOLOGY, INC. NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER (As adopted on August 6, 2022) Purpose The purpose of the Nominating and Corporate Governance Committee (the “Committee”) of the Board of Directors (the “Board”) of Curative Biotechnology, Inc. (the “Company”) is to assist the Board in the discharge of its responsibilities relating to: (a) the identifi

Compensation Committee Charter

Exhibit 99.02 CURATIVE BIOTECHNOLOGY, INC. COMPENSATION COMMITTEE CHARTER (As adopted on August 6, 2022) Purpose The purpose of the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Curative Biotechnology, Inc. (the “Company”) is to assist the Board in the discharge of its responsibilities relating to: (a) the compensation of the Company’s directors and officers;

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

As filed with the Securities and Exchange Commission on August 10, 2022

As filed with the Securities and Exchange Commission on August 10, 2022 Registration No.

Registration Fee Table

EX-FILING FEES 6 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off

August 10, 2022

August 10, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Laura Crotty Re: Curative Biotechnology, Inc. Registration Statement on Form S-1 Filed August 1, 2022 File No. 333-264339 Ladies and Gentlemen: On behalf of Curative Biotechnology, In

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

As filed with the Securities and Exchange Commission on August 1, 2022

As filed with the Securities and Exchange Commission on August 1, 2022 Registration No.

Form of Underwriter Warrant

EX-4.20 5 ex4-20.htm Exhibit 4.20 THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING [●]

Underwriter Agreement

Exhibit 1.01 Underwriting Agreement [?], 2022 Aegis Capital Corp. 810 7th Avenue, 18th Floor New York, NY 10019 Ladies and Gentlemen: Curative Biotechnology, Inc., a Florida corporation (the ?Company?), agrees, subject to the terms and conditions in this agreement (this ?Agreement?), to issue and sell to Aegis Capital Corp. (the ?Underwriter?) an aggregate of [?] units (each, a ?Closing Unit?), wi

Registration Fee Table

EX-FILING FEES 7 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount o

Form of Common Stock Purchase Warrant issued in Aegis Capital Underwritten Offering

Exhibit 4.18 COMMON STOCK PURCHASE WARRANT Curative biotechnology, inc. Warrant Shares: Initial Exercise Date: Issue Date: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder,” provided that a “Holder” shall include, if the Warrants are held in “street name,” a Participant, any designee appointed by such Participant and each “beneficia

Form of Warrant Agent Agreement between Curative Biotechnology and Issuer Direct Corporation

EX-4.19 4 ex4-19.htm Exhibit 4.19 WARRANT AGENT AGREEMENT This WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of [●], 2022 (the “Issuance Date”) is between Curative Biotechnology, Inc., a Florida corporation (the “Company”), and Issuer Direct Corporation (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated [●],

July 8, 2022

CORRESP 1 filename1.htm July 8, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Laura Crotty Re: Curative Biotechnology, Inc. Registration Statement on Form S-1 Filed June 29, 2022 File No. 333-264339 Ladies and Gentlemen: On behalf of Curati

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

As filed with the Securities and Exchange Commission on July 8, 2022

As filed with the Securities and Exchange Commission on July 8, 2022 Registration No.

Registration Fee Table

EX-FILING FEES 11 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1) Fee Rate Amount

Registration Fee Table

EX-FILING FEES 3 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Curative Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Off

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

As filed with the Securities and Exchange Commission on June 29, 2022

As filed with the Securities and Exchange Commission on June 29, 2022 Registration No.

April 25, 2022

CORRESP 1 filename1.htm April 25, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Laura Crotty Re: Curative Biotechnology, Inc. Registration Statement on Form S-1 Filed April 15, 2022 File No. 333-264339 Ladies and Gentlemen: On behalf of Cur

Code of Ethics and Business Conduct

Exhibit 14.01 Curative Biotechnology, Inc. Code of Ethics and Business Conduct 1. Introduction. 1.1 The Board of Directors (?Board?) of Curative Biotechnology, Inc. (together with its subsidiaries, the ?Company?) has adopted this Code of Ethics and Business Conduct (the ?Code?) in order to: (a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of in

Cooperative Research and Development Agreement for Intramura-PhS Clinical Research

Exhibit 10.22 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH This Agreement is based on the model Cooperative Research and Development Agreement (?CRADA?) adopted by the U.S. Public Health Service (?PHS?) Technology Transfer Policy Board for use by components of the National Institutes of Health (?NIH?), the Centers for Disease Control and

As filed with the Securities and Exchange Commission on April 25, 2022

As filed with the Securities and Exchange Commission on April 25, 2022 Registration No.

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

Form of Stock Option Grant for 2021 Equity Incentive Plan

Exhibit 4.15 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Curative Biotechnology, Inc. 2021 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the ?Notice of Grant?), the Terms and Conditions of Stock Option

2021 Equity Incentive Plan

Exhibit 4.14 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan . The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock

Form of Common Stock Purchase Warrant issued to Investors in August 2021

Exhibit 4.06 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Note Issued to Investors between November 2020 and January 2021

Exhibit 10.03 FIXED PAYMENT BRIDGE NOTE LENDER: [*] BORROWER: Connectyx Group Holdings Company, Inc. A Florida corporation whose address is 1825 NW Corporate Blvd. Boca Raton Florida, 33431 CLOSING DATE: [*] BORROWERS PROMISE TO PAY: $[*]([*] DOLLARS), an amount referred to as the” payment amount” in return for the loan that Borrower has received for $[*] ([*] DOLLARS) to the Lender on or before t

Form of Securities Purchase Agreement for March 2022 Offering

Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the ?Company?) and the Purchaser identified on the signature pages hereto (including their successors and assigns

Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

Exhibit 10.11 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT ? EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (?PHS?) Technology Transfer Policy Board for use by components of the National Institutes of Health (?NIH?), the Centers for Disease Control and Prevention (?CDC?), and the Food and Drug Administration (?FDA?), wh

Exclusive Option Agreement for Purchase of Patent Rights dated September 30, 2020 between Curative Biotechnology (fka Connectyx Technologies Holdings Group) and IEM Inc.

Exhibit 10.10 EXCLUSIVE OPTION AGREEMENT FOR PURCHASE OF PATENT RIGHTS This Agreement is made as of the date set forth above the signatures of the parties below (the ?EFFECTIVE DATE?), by and between IEM INC., A Florida Corporation located in Palm Beach County (?IEM?) and CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC., A Florida Corporation located in Palm Beach County (?CONNECTYX?). RECITALS: A. WHE

Employment Agreement with Richard Garr dated October 1, 2020

Exhibit 10.06 EMPLOYMENT AGREEMENT Employment agreement (?the Agreement?) dated as of October 1, 2020 between Connectyx Technologies Holdings Group 1825 NW Corporate Boulevard, Suite 110 Boca Raton, FL 33431 (?the Company?) and I Richard Garr, an individual with an address of 1024 Casuarina Road Delray Beach, FL 33483 (?the employee?) WHEREAS, the Company desires to retain the services of Employee

Form of Restricted Stock Award Agreement for 2021 Equity Incentive Plan

Exhibit 4.16 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Curative Biotechnology, Inc. 2021 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Restricted Stock Award Agreement (the ?Award Agreement?). I. NOTICE OF RESTRICTED STOCK GRANT Participant Name: Address: You ha

Form of Consultant Warrants issued between December 2020 and January 2021

Exhibit 4.10 WARRANT: B-[*] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E

Specimen Series A Preferred Stock

Exhibit 4.02

Amended and Restated Bylaws of Curative Biotechnology, Inc. dated March 29, 2021

Exhibit 3.02(ii) AMENDED AND RESTATED BYLAWS OF CURATIVE BIOTECHNOLOGY, INC. (amended and restated on March 29, 2021) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Curative Biotechnology, Inc. shall be as designated in its certificate of incorporation, as may be amended and restated (?Certificate?) and as may be amended or changed by the corporation?s board of directo

Form of Subscription Agreement for Investor Offerings in August 2021

Exhibit 10.01 [DATE] Curative Biotechnology, Inc. Attn: I. Richard Garr, President 1825 NW Corporate Blvd. Boca Raton, FL 33431 Email: [*] Re: Curative Biotechnology, Inc. - Subscription for Shares of Common Stock Ladies and Gentlemen: The undersigned hereby acknowledges and agrees to the following: 1. The undersigned hereby subscribes for [*] Units, with each Unit consisting of: (i) [?] shares of

Calculation of Registration Fee

EX-FILING FEES 46 ex107.htm Calculation of Registration Fee Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price (1)(2) Amount of Registration Fee(3) Units consisting of: (i) One share of common stock, $0.0001 par value (ii)Warrants to purchase shares of common stock(4) Shares of common stock issuable upon exercise of warrants TOTAL REGISTRATION FEE $ $ (1)

Settlement Agreement dated August 9, 2021

Exhibit 10.04 SETTLEMENT AGREEMENT AND RELEASE THIS SETTLEMENT AGREEMENT AND RELEASE (the ?Settlement Agreement?), is made and entered into as of this 9th day of August 2021 by and between: (i) (?[*]?) and (?[*]?) on the one hand; and CURATIVE BIOTECHNOLOGY, INC. f/k/a CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC., on the other hand (?Curative? and together with [*] and [*], the ?Parties?). RECITALS

Form of Subscription Agreement for Investor Offerings on May 21, 2021

Exhibit 10.02 May 21, 2021 Curative Biotechnology, Inc. Attn: I. Richard Garr, President 1825 NW Corporate Blvd. Boca Raton, FL 33431 Email: [email protected] Re: Curative Biotechnology, Inc. - Subscription for Shares of Common Stock Ladies and Gentlemen: The undersigned hereby acknowledges and agrees to the following: 1. The undersigned hereby subscribes for 10,000,000 shares (the ?Shares?) of Common

April 15, 2022

CORRESP 1 filename1.htm April 15, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Laura Crotty Re: Curative Biotechnology, Inc. Registration Statement on Form S-1 Submitted January 10, 2022 CIK No. 0001400271 Ladies and Gentlemen: On behalf o

Form of Warrant issued to Investors in Note Offering from November 2020 through January 2021

Exhibit 4.08 WARRANT: A-[*] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E

Specimen of Common Stock Certificate

Exhibit 4.01

Fourth Amended and Restated Articles of Incorporation dated January 27, 2021

Exhibit 3.01 FOURTH AMENDED AND RESTATED ARTICLES OF INCORPORATION OF CURATIVE BIOTECHNOLOGY, INC. January 27, 2021 Paul M Michaels, being the CEO and Director of Curative Biotechnology, Inc., a corporation duly organized under the Business Corporation Act of the State of Florida (the ?Corporation?), hereby certifies that: 1. The name of the Corporation is Curative Biotechnology, Inc. 2. The Corpo

First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc.

Exhibit 10.15 FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENT THIS FIRST AMENDMENT (the ?Amendment?) to the License, Funding and Operational Agreement between Mid-Atlantic BioTherapeutics, Inc. (?Licensor?) and Curative Biotechnology, Inc. (?Licensee?) executed October 1, 2021 for a COVID-19 Vaccine (the ?Agreement?), is made by Licensor and Licensee, WITNESSETH: WHEREAS, the Licenso

Consent of Daszkal Bolton LLP

Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Curative Biotechnology, Inc. Boca Raton, Florida We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement on Form S-1 of Curative Biotechnology, Inc. of our report dated March 25, 2022 relating to the financial statements at and for the years ended December 31, 202

Form of Lock Up Agreement for March 2022 Offering

Exhibit 10.21 LOCK-UP AGREEMENT March 2, 2022 Each Purchaser referenced below: Re: Securities Purchase Agreement, dated as of March 2, 2022 (the “Purchase Agreement”), between Curative Biotechnology, Inc., a Florida corporation (the “Company”), and the purchaser signatory thereto (the “Purchaser”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agree

Compensation Committee Charter

Exhibit 99.02 Compensation Committee Charter Purpose The purpose of the Compensation Committee (the Committee) is to oversee Curative Biotechnology’s compensation programs. The Committee will provide this oversight through a process that supports Curative Biotechnology’s business objectives and incorporates sound corporate governance principles. The Committee will also broadly oversee matters rela

Audit Committee Charter

Exhibit 99.01 Audit Committee Charter Purpose The purpose of the Audit Committee (the Committee) is to: ? Oversee Curative Biotechnology?s accounting and financial reporting processes, including Curative Biotechnology?s disclosure controls and procedures and system of internal controls and audits of Curative Biotechnology?s financial statements. ? Oversee Curative Biotechnology?s relationship with

Form of Common Stock Purchase Warrant issued to Marc Drimer on July 14, 2021

Exhibit 4.12 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

Exhibit 10.13 LICENSE, FUNDING AND OPERATIONAL AGREEMENT This License Agreement (this ?Agreement?) is made and is effective this 30th day of September, 2020, (the ?Effective Date?) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (?Licensor?) and Connectyx (hereinafter CTYX) Technologies Holdings Group, Inc., a Florida corporation (?Licensee?), and David Horn, L

Governance and Nominating Committee Charter

EX-99.03 45 ex99-03.htm Exhibit 99.03 Governance and Nominating Committee Charter Purpose The purpose of the Governance and Nominating Committee (Committee) is to: ● Assist the Board of Directors (Board) by identifying individuals qualified to become Board members, consistent with criteria approved by the Board. ● Assist the Board CEO succession planning including: identifying qualified individual

Form of Warrant issued to investors on May 21, 2021

Exhibit 4.07 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Cooperative Research and Development Agreement for Intramura-PhS Clinical Research

Exhibit 10.22 PUBLIC HEALTH SERVICE COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCH This Agreement is based on the model Cooperative Research and Development Agreement (?CRADA?) adopted by the U.S. Public Health Service (?PHS?) Technology Transfer Policy Board for use by components of the National Institutes of Health (?NIH?), the Centers for Disease Control and

Form of Secured Convertible Promissory Note for March 2022 Offering

Exhibit 10.17 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI

First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc.

Exhibit 10.14 FIRST AMENDMENT TO LICENSE, FUNDING AND OPERATIONAL AGREEMENT THIS IS THE FIRST AMENDMENT (the ?Amendment?) to the License, Funding and Operational Agreement for rabies immunotherapy (the ?Agreement?) between Mid-Atlantic BioTherapeutics, Inc. (?Licensor?) and Curative Biotechnology, Inc., formerly Connectyx, (?Licensee?) originally executed September 30th, 2020. WITNESSETH: WHEREAS,

Form of Common Stock Purchase Warrant issued to Paul Michaels on June 11, 2021

Exhibit 4.11 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Restricted Stock Unit Agreement for 2021 Equity Incentive Plan

EX-4.17 19 ex4-17.htm Exhibit 4.17 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Curative Biotechnology, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement, which includes the Notice of Restri

Form of Common Stock Purchase Warrant issued to Certain Consultants in May 2021

Exhibit 4.05 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Form of Intellectual Property Security Agreement for March 2022 Offering

Exhibit 10.19 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (“IP Security Agreement”) dated as of March 2, 2022, is made and entered into by and among Curative Biotechnology, Inc., a Florida corporation (the “Company”), any subsidiary of the Company that is a signatory hereto either now joined or joined in the future (such subsidiaries, together with the Co

License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc.

Exhibit 10.09 LICENSE, FUNDING AND OPERATIONAL AGREEMENT This License Agreement (this ?Agreement?) is made and is effective this 1st day of October 2021, (the ?Effective Date?) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (?Licensor?) and Curative Biotechnology, Inc. (hereinafter CUBT), a Delaware corporation (?Licensee?), and David Horn, LLC as Licensor to

Employment Agreement with Paul Michaels dated October 1, 2020

Exhibit 10.08 EMPLOYMENT AGREEMENT Employment agreement (?the Agreement?) dated as of October 1, 2020 between Connectyx Technologies Holdings Group 1825 NW Corporate Boulevard, Suite 110 Boca Raton, FL 33431 (?the Company?) and Paul M. Michaels, an individual with an address of 7922 La Mirada Drive Boca Raton, FL 33433 (?the employee?) WHEREAS, the Company desires to retain the services of Employe

As filed with the Securities and Exchange Commission on April 15, 2022

As filed with the Securities and Exchange Commission on April 15, 2022 Registration No.

Form of Common Stock Purchase warrant issued to Consultant on December 3, 2020

Exhibit 4.09 WARRANT: B-[*] NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN E

Specimen of Series B Preferred Stock

Exhibit 4.03

Form of Warrant for March 2022 Offering

Exhibit 10.20 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Form of Security Agreement for March 2022 Offering

Exhibit 10.18 SECURITY AGREEMENT SECURITY AGREEMENT, dated as of March 2, 2022 (this ?Agreement?), between Curative Biotechnology, Inc., a Florida limited liability company (the ?Company? or the ?Debtor? and collectively with any other Debtor from time to time hereunder, the ?Debtors?) and the holders of the Company?s 12.5% Senior Secured Note due March 2, 2023 in aggregate principal amount of $1,

Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group)

Exhibit 10.12 PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT – EXCLUSIVE EVALUATION OPTION LICENSE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug

Specimen of Series C Preferred Stock

Exhibit 4.04

Employment Agreement with Barry Ginsberg dated October 1, 2020

EX-10.07 26 ex10-07.htm Exhibit 10.07 EMPLOYMENT AGREEMENT Employment agreement (“the Agreement”) dated as of October 1, 2020 between Connectyx Technologies Holdings Group 1825 NW Corporate Boulevard, Suite 110 Boca Raton, FL 33431 (“the Company”) and Dr. Barry A. Ginsberg, an individual with an address of 3601 NW 24th Avenue, Boca Raton, FL 33431 (“the employee”) WHEREAS, the Company desires to r

Consulting Agreement dated September 27, 2021

Exhibit 10.05 Sohn Health Strategies SPECIAL ADVISOR TO THE BOARD OF DIRECTORS AND THE CEO AGREEMENT THIS AGREEMENT is made and entered into effective as of SEPTEMBER 27, 2021, (the ?Effective Date?), by and between Curative Biotechnology Inc., a Florida corporation (the ?Company?) with its principal place of business located at 1825 NW Corporate Blvd #110 Boca Raton, Florida , and Sohn Health Str

March 28, 2022

DRSLTR 1 filename1.htm March 28, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Laura Crotty Re: Curative Biotechnology, Inc. Registration Statement on Form S-1 Submitted January 10, 2022 CIK No. 0001400271 Ladies and Gentlemen: On behalf of

INTELLECTUAL PROPERTY SECURITY AGREEMENT

EX-10.19 5 filename5.htm Exhibit 10.19 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement (“IP Security Agreement”) dated as of March 2, 2022, is made and entered into by and among Curative Biotechnology, Inc., a Florida corporation (the “Company”), any subsidiary of the Company that is a signatory hereto either now joined or joined in the future (such subsidiar

EX-10.22

EX-10.22 8 filename8.htm Exhibit 10.22

SECURITIES PURCHASE AGREEMENT

EX-10.16 2 filename2.htm Exhibit 10.16 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as March 2, 2022, among Curative Biotechnology, Inc, a Florida corporation whose principal place of business is located at 1825 NW Corporate Blvd., Suite 110 Boca Raton, FL 33431 (the “Company”) and the Purchaser identified on the signature pages hereto (including the

12.5% ORIGINAL ISSUE DISCOUNT SENIOR SECURED NOTE Due March 2, 2023

EX-10.17 3 filename3.htm Exhibit 10.17 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURS

COMMON STOCK PURCHASE WARRANT CURATIVE BIOTECHNOLOGY, INC.

EX-10.20 6 filename6.htm Exhibit 10.20 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSU

As confidentially submitted to the Securities and Exchange Commission on March 25, 2022, pursuant to the Jumpstart our Business Startups Act of 2012. As filed with the Securities and Exchange Commission on March 25, 2022

As confidentially submitted to the Securities and Exchange Commission on March 25, 2022, pursuant to the Jumpstart our Business Startups Act of 2012.

SECURITY AGREEMENT

EX-10.18 4 filename4.htm Exhibit 10.18 SECURITY AGREEMENT SECURITY AGREEMENT, dated as of March 2, 2022 (this “Agreement”), between Curative Biotechnology, Inc., a Florida limited liability company (the “Company” or the “Debtor” and collectively with any other Debtor from time to time hereunder, the “Debtors”) and the holders of the Company’s 12.5% Senior Secured Note due March 2, 2023 in aggregat

LOCK-UP AGREEMENT

EX-10.21 7 filename7.htm Exhibit 10.21 LOCK-UP AGREEMENT March 2, 2022 Each Purchaser referenced below: Re: Securities Purchase Agreement, dated as of March 2, 2022 (the “Purchase Agreement”), between Curative Biotechnology, Inc., a Florida corporation (the “Company”), and the purchaser signatory thereto (the “Purchaser”) Ladies and Gentlemen: Defined terms not otherwise defined in this letter agr

EX-10.13

EX-10.13 202 filename202.htm Exhibit 10.13

COMMON STOCK PURCHASE WARRANT CURATIVE BIOTECHNOLOGY, INC.

Exhibit 4.06 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

EX-4.08

Exhibit 4.08

EX-4.10

Exhibit 4.10

COMMON STOCK PURCHASE WARRANT CURATIVE BIOTECHNOLOGY, Inc.

Exhibit 4.11 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT

Exhibit 4.16 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the Curative Biotechnology, Inc. 2021 Equity Incentive Plan (the ?Plan?) will have the same defined meanings in this Restricted Stock Award Agreement (the ?Award Agreement?). I. NOTICE OF RESTRICTED STOCK GRANT Participant Name: Address: You ha

Governance and Nominating Committee Charter

Exhibit 99.03 Governance and Nominating Committee Charter Purpose The purpose of the Governance and Nominating Committee (Committee) is to: ? Assist the Board of Directors (Board) by identifying individuals qualified to become Board members, consistent with criteria approved by the Board. ? Assist the Board CEO succession planning including: identifying qualified individuals, consistent with the c

CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN

Exhibit 4.14 CURATIVE BIOTECHNOLOGY, INC. 2021 EQUITY INCENTIVE PLAN 1. Purposes of the Plan . The purposes of this Plan are: ? to attract and retain the best available personnel for positions of substantial responsibility, ? to provide additional incentive to Employees, Directors and Consultants, and ? to promote the success of the Company?s business. The Plan permits the grant of Incentive Stock

As confidentially submitted to the Securities and Exchange Commission on January 10, 2022, pursuant to the Jumpstart our Business Startups Act of 2012. As filed with the Securities and Exchange Commission on January 10, 2022

As confidentially submitted to the Securities and Exchange Commission on January 10, 2022, pursuant to the Jumpstart our Business Startups Act of 2012.

January 10, 2022

January 10, 2022 Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Bennett, Vanessa Robertson, Jason Drory, and Laura Crotty Re: Curative Biotechnology, Inc. Registration Statement on Form S-1 Submitted November 24, 2021 CIK No. 0001400271 Ladies and Gentlemen: On behalf of Curative Biotechnol

EX-10.04

Exhibit 10.04

Curative Biotechnology, Inc. Code of Ethics and Business Conduct

EX-14.01 228 filename228.htm Exhibit 14.01 Curative Biotechnology, Inc. Code of Ethics and Business Conduct 1. Introduction. 1.1 The Board of Directors (“Board”) of Curative Biotechnology, Inc. (together with its subsidiaries, the “Company”) has adopted this Code of Ethics and Business Conduct (the “Code”) in order to: (a) promote honest and ethical conduct, including the ethical handling of actua

AMENDED AND RESTATED BYLAWS CURATIVE BIOTECHNOLOGY, INC. (amended and restated on March 29, 2021) ARTICLE I CORPORATE OFFICES

Exhibit 3.02(ii) AMENDED AND RESTATED BYLAWS OF CURATIVE BIOTECHNOLOGY, INC. (amended and restated on March 29, 2021) ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE. The registered office of Curative Biotechnology, Inc. shall be as designated in its certificate of incorporation, as may be amended and restated (?Certificate?) and as may be amended or changed by the corporation?s board of directo

EX-10.15

EX-10.15 226 filename226.htm Exhibit 10.15